GCTK Form 4: Director holdings rise to 2,148 shares; $7.4 options

Rhea-AI Filing Summary

Glucotrack, Inc. (GCTK) director Erin Catherine Carter reported multiple equity awards and exercises that increased her direct common stock holdings and option position. On 03/25/2025 she was recorded as acquiring 32 shares, followed by 1,000 shares on 07/11/2025 and 386 shares on 10/03/2025, bringing total directly held common stock to 2,148 shares after those transactions. The filing also shows an option grant exercisable beginning 10/03/2025 for 4,055 shares with an exercise price of $7.4 and an expiration in 10/03/2035. The Form 4 notes standard vesting that begins on July 1 of the applicable year and vests monthly over 12 months, and it discloses that reported share figures reflect a series of reverse stock splits implemented in 2024, 02/25/2025, and 06/13/2025.

Positive

• Director increased direct ownership to 2,148 shares, signaling continued insider participation
• Option grant of 4,055 shares provides long‑dated alignment through 10/03/2035

Negative

• Exercise price of $7.4 may be above recent market levels (market level not provided in filing)
• Vesting tied to continued service, so shares/options are subject to forfeiture if service ends before vesting

Insights

Corporate Governance Analyst

Director received scheduled equity awards and increased direct ownership.

The transactions show a director-level recipient acquiring 2,148 common shares through three non‑derivative acquisitions across 03/25/2025 to 10/03/2025

These moves follow standard equity grant mechanics with a stated monthly vesting schedule commencing on July 1; the board-level status is relevant because director holdings affect alignment with shareholders and governance optics over the next 12 months.

Equity Compensation Specialist

A stock option for 4,055 shares at $7.4 vests monthly and expires on 10/03/2035.

The option's exercise price and ten‑year term are explicitly stated and the filing ties vesting to continued service, with monthly vesting over a 12‑month period after the July 1 start.

Because the filing reflects multiple reverse stock splits, the share counts are adjusted; investors tracking dilution should compare post‑split figures to outstanding share totals on the same post‑split basis within the same timeframe.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Carter Erin Catherine

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	4,055	$0.00	--
Grant/Award	Common Stock, par value $0.001 per share	386	$0.00	--
Grant/Award	Common Stock, par value $0.001 per share	1,000	$0.00	--
Grant/Award	Common Stock, par value $0.001 per share	32	$0.00	--

Holdings After Transaction: Stock option (right to buy) — 4,055 shares (Direct); Common Stock, par value $0.001 per share — 2,148 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carter Erin Catherine

(Last) (First) (Middle)

C/O GLUCOTRACK, INC.

301 RTE 17 NORTH, STE. 800

(Street)

RUTHERFORD NJ 07070

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Glucotrack, Inc. [ GCTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.001 per share	03/25/2025		A		32	A	$0	762	D
Common Stock, par value $0.001 per share	07/11/2025		A		1,000	A	$0	1,762	D
Common Stock, par value $0.001 per share	10/03/2025		A		386	A	$0	2,148	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$7.4	10/03/2025		A		4,055		(1)	10/03/2035	Common Stock, par value $0.001 per share	4,055	$0	4,055	D

Explanation of Responses:

1. Each option grant has a vesting commencement date of July 1 of the applicable calendar year and vests in 12 equal monthly installments over the 12-month period ending June 30 of the following year, subject to the reporting person's continued service to the Issuer through each vesting date.

Remarks:

On May 17, 2024, a 1-for-5 reverse stock split of the Issuer's common stock, par value $0.001 per share (the "Common Stock") was implemented (the "2024 Reverse Split"). On February 25, 2025, a 1-for-20 reverse stock split of the Common Stock was implemented (the "February 2025 Reverse Split"), and on June 13, 2025, a 1-for-60 reverse stock split of the Common Stock was implemented (the "June 2025 Reverse Stock Split", and together with the 2024 Reverse Split and the February 2025 Reverse Stock Split, the "Reverse Stock Splits"). All figures presented in this Form 4 reflect the Reverse Stock Splits.

	/s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact	10/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Erin Catherine Carter report on Form 4 for GCTK?

The filing reports acquisitions of 32 shares on 03/25/2025, 1,000 shares on 07/11/2025, and 386 shares on 10/03/2025, plus a stock option for 4,055 shares exercisable from 10/03/2025 at $7.4.

How many total common shares does the director hold after these transactions?

The director's reported beneficial ownership following the listed non‑derivative transactions is 2,148 shares.

What are the key terms of the option reported in the Form 4 for GCTK?

The option covers 4,055 underlying shares, has an exercise price of $7.4, becomes exercisable on 10/03/2025, and expires on 10/03/2035.

Do the reported share counts reflect any corporate actions?

Yes; the Form 4 states that all figures reflect reverse stock splits on May 17, 2024, 02/25/2025, and 06/13/2025.

What is the vesting schedule for the reported option grants?

Each option grant has a vesting commencement date of July 1 of the applicable year and vests in 12 equal monthly installments over the following 12 months, subject to continued service.